DDP 225

Drug Profile

DDP 225

Latest Information Update: 29 Dec 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mitsubishi Chemical
  • Developer Dynogen Pharmaceuticals
  • Class Analgesics; Antidepressants; Irritable bowel syndrome therapies; Nootropics; Pyrimidines; Small molecules; Urologics
  • Mechanism of Action Adrenergic receptor antagonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Irritable bowel syndrome; Major depressive disorder; Nausea and vomiting; Overactive bladder

Most Recent Events

  • 23 May 2008 Adverse events data from a Phase-IIa trial in Irritable bowel syndrome presented at the Digestive Disease Week 2008 (DDW-2008)
  • 17 Jan 2008 Patent rights and know-how relating to DDP 225 transferred from Arachnova Therapeutics to Dynogen Pharmaceuticals through an asset purchase agreement
  • 20 Dec 2007 Discontinued - Phase-II for Nausea and vomiting in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top